A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

NCT05622708 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-radiographic Axial Spondyloarthritis

Interventions

DRUG: Secukinumab
DRUG: Placebo
DRUG: Secukinumab

Sponsor

Novartis Pharmaceuticals